Nutriband reports 2023 EPS (53c) vs. (80c) last year

Reports 2023 revenue $2.1M vs. $1.4M last year. "Our 2022 results and milestones have shown that we remain laser focused on hitting the targets we set ourselves as a company each year. We have made significant progress with AVERSA and our goal to improve the safety profile of easily abused transdermal drugs. Our record financial results and multiple major achievements in fiscal 2022 were a direct result of the hard work and exceptional execution of our dedicated team," commented Gareth Sheridan, CEO of Nutriband. "We look forward to continuing to positively update our shareholders as we have laid out major milestone targets for 2023 which we intend to achieve as in previous years.’ According to an assessment by Health Advances, AVERSA Fentanyl could reach peak annual sales of between $80 million and $200 million. If the entire transdermal fentanyl market moves toward abuse deterrent patches, similar to what occurred in the extended-release oral opioid market, the potential could be significantly greater," continued Sheridan. "I want to thank our shareholders for their ongoing support as we continue to execute on our vision of commercializing our innovative transdermal abuse deterrent technology, AVERSA(TM)."